©2024 Stanford Medicine
Bumetanide in Patients With Alzheimer's Disease
Recruiting
I'm InterestedTrial ID: NCT06052163
Purpose
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's
disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the
treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been
proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent
transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was
subsequently explored in Electronic Health Record cohorts, which revealed that among
individuals over the age of 65, bumetanide exposure was significantly associated with a lower
prevalence of AD in three independent datasets.
Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to
participants with biomarker-confirmed Alzheimer's disease.
Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in
participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Official Title
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
Stanford Investigator(s)
Kyan Younes, MD
Clinical Assistant Professor, Neurology & Neurological Sciences
Eligibility
Inclusion Criteria:
- Mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Alzheimer's disease medications are planned to remain stable throughout.
- Willingness and ability to complete all aspects of the study including assessments,
neuropsychological testing, and MRI.
Exclusion Criteria:
- Clinically significant abnormalities in screening laboratory tests
- Chronic liver disease
- Renal insufficiency
- Poorly managed hypertension
- Participants taking the following concomitant medications, based on the current
Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs
with nephrotoxic potential, probenecid, and indomethacin.
Intervention(s):
drug: Bumetanide
drug: Placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mina L Kim
650-387-1559